|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duxbury MS, Ito H, Benoit E, Waseem T,
Ashley SW and Whang EE: RNA interference demonstrates a novel role
for integrin-linked kinase as a determinant of pancreatic
adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res.
11:3433–3438. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jia Z: Role of integrin-linked kinase in
drug resistance of lung cancer. Onco Targets Ther. 8:1561–1565.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McDonald PC and Dedhar S: New perspectives
on the role of integrin-linked kinase (ILK) signaling in cancer
metastasis. Cancers (Basel). 14:32092022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McDonald PC, Fielding AB and Dedhar S:
Integrin-linked kinase-essential roles in physiology and cancer
biology. J Cell Sci. 121:3121–3132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ning Z, Zhu X, Jiang Y, Gao A, Zou S, Gu
C, He C, Chen Y, Ding WQ and Zhou J: Integrin-linked kinase is
involved in the proliferation and invasion of esophageal squamous
cell carcinoma. J Cancer. 11:324–333. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ji C, Zhang M, Hu J, Cao C, Gu Q, Liu Y,
Li X, Xu D, Ying L, Yang Y, et al: The kinase activity of
integrin-linked kinase regulates cellular senescence in gastric
cancer. Cell Death Dis. 13:5772022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li B, Wang X, Wang R, Rutz B, Ciotkowska
A, Gratzke C, Herlemann A, Spek A, Tamalunas A, Waidelich R, et al:
Inhibition of neurogenic and thromboxane A2-induced
human prostate smooth muscle contraction by the integrin α2β1
inhibitor BTT-3033 and the integrin-linked kinase inhibitor Cpd22.
Prostate. 80:831–849. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarı Kılıçaslan SM and İncesu Z: Effects
of integrin-linked kinase on protein kinase b, glycogen synthase
kinase-3β, and β-catenin molecules in ovarian cancer cells. Iran J
Basic Med Sci. 24:1500–1508. 2021.PubMed/NCBI
|
|
13
|
Yau CY, Wheeler JJ, Sutton KL and Hedley
DW: Inhibition of integrin-linked kinase by a selective small
molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and
FKHR pathways and tumor growth, and enhances gemcitabine-induced
apoptosis in human orthotopic primary pancreatic cancer xenografts.
Cancer Res. 65:1497–1504. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng S, Pöttler M, Lan B, Grützmann R,
Pilarsky C and Yang H: Chemoresistance in Pancreatic Cancer. Int J
Mol Sci. 20:45042019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Imafuji H, Matsuo Y, Ueda G, Omi K,
Hayashi Y, Saito K, Tsuboi K, Morimoto M, Koide S, Ogawa R, et al:
Acquisition of gemcitabine resistance enhances angiogenesis via
upregulation of IL8 production in pancreatic cancer. Oncol Rep.
41:3508–3516. 2019.PubMed/NCBI
|
|
16
|
Bustin SA: Quantification of mRNA using
real-time reverse transcription PCR (RT-PCR): trends and problems.
J Mol Endocrinol. 29:23–39. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Serrano I, McDonald PC, Lock F, Muller WJ
and Dedhar S: Inactivation of the Hippo tumour suppressor pathway
by integrin-linked kinase. Nat Commun. 4:29762013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takanami I: Increased expression of
integrin-linked kinase is associated with shorter survival in
non-small cell lung cancer. BMC Cancer. 5:12005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ahmed N, Riley C, Oliva K, Stutt E, Rice
GE and Quinn MA: Integrin-linked kinase expression increases with
ovarian tumour grade and is sustained by peritoneal tumour fluid. J
Pathol. 201:229–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marotta A, Parhar K, Owen D, Dedhar S and
Salh B: Characterisation of integrin-linked kinase signalling in
sporadic human colon cancer. Br J Cancer. 88:1755–1762. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bravou V, Klironomos G, Papadaki E,
Stefanou D and Varakis J: Integrin-linked kinase (ILK) expression
in human colon cancer. Br J Cancer. 89:2340–2341. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ito R, Oue N, Zhu X, Yoshida K, Nakayama
H, Yokozaki H and Yasui W: Expression of integrin-linked kinase is
closely correlated with invasion and metastasis of gastric
carcinoma. Virchows Arch. 442:118–123. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peroukides S, Bravou V, Varakis J,
Alexopoulos A, Kalofonos H and Papadaki H: ILK overexpression in
human hepatocellular carcinoma and liver cirrhosis correlates with
activation of Akt. Oncol Rep. 20:1337–1344. 2008.PubMed/NCBI
|
|
24
|
Sawai H, Okada Y, Funahashi H, Matsuo Y,
Takahashi H, Takeyama H and Manabe T: Integrin-linked kinase
activity is associated with interleukin-1 alpha-induced progressive
behavior of pancreatic cancer and poor patient survival. Oncogene.
25:3237–3246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Troussard AA, Mawji NM, Ong C, Mui A,
St–Arnaud R and Dedhar S: Conditional knock-out of integrin-linked
kinase demonstrates an essential role in protein kinase B/Akt
activation. J Biol Chem. 278:22374–22378. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qu Y, Hao C, Xu J, Cheng Z, Wang W and Liu
H: ILK promotes cell proliferation in breast cancer cells by
activating the PI3K/Akt pathway. Mol Med Rep. 16:5036–5042. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schlieman MG, Fahy BN, Ramsamooj R,
Beckett L and Bold RJ: Incidence, mechanism and prognostic value of
activated AKT in pancreas cancer. Br J Cancer. 89:2110–2115. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heerding DA, Rhodes N, Leber JD, Clark TJ,
Keenan RM, Lafrance LV, Li M, Safonov IG, Takata DT, Venslavsky JW,
et al: Identification of 4- (2- (4- amino- 1,2,5- oxadiazol- 3-
yl)- 1- ethyl- 7- {[(3S)- 3-piperidinylmethyl]oxy}-
1H-imidazo[4,5-c]pyridin- 4-yl)- 2- methyl- 3- butyn- 2- ol
(GSK690693), a novel inhibitor of AKT kinase. J Med Chem.
51:5663–5679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kato T, Matsuo Y, Ueda G, Murase H, Aoyama
Y, Omi K, Hayashi Y, Imafuji H, Saito K, Morimoto M, et al:
Enhanced CXCL12/CXCR4 signaling increases tumor progression in
radiation-resistant pancreatic cancer. Oncol Rep. 47:682022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maier HJ, Schmidt-Strassburger U, Huber
MA, Wiedemann EM, Beug H and Wirth T: NF-kappaB promotes
epithelial-mesenchymal transition, migration and invasion of
pancreatic carcinoma cells. Cancer Lett. 295:214–228. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zheng CC, Hu HF, Hong P, Zhang QH, Xu WW,
He QY and Li B: Significance of integrin-linked kinase (ILK) in
tumorigenesis and its potential implication as a biomarker and
therapeutic target for human cancer. Am J Cancer Res. 9:186–197.
2019.PubMed/NCBI
|
|
33
|
Tan C, Cruet-Hennequart S, Troussard A,
Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J and
Dedhar S: Regulation of tumor angiogenesis by integrin-linked
kinase (ILK). Cancer Cell. 5:79–90. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stipa F, Lucandri G, Limiti MR, Bartolucci
P, Cavallini M, Di Carlo V, D'Amato A, Ribotta G and Stipa S:
Angiogenesis as a prognostic indicator in pancreatic ductal
adenocarcinoma. Anticancer Res. 22:445–449. 2002.PubMed/NCBI
|
|
35
|
Benckert C, Thelen A, Cramer T, Weichert
W, Gaebelein G, Gessner R and Jonas S: Impact of microvessel
density on lymph node metastasis and survival after curative
resection of pancreatic cancer. Surg Today. 42:169–176. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Matsuo Y, Ochi N, Sawai H, Yasuda A,
Takahashi H, Funahashi H, Takeyama H, Tong Z and Guha S: CXCL8/IL-8
and CXCL12/SDF-1alpha co-operatively promote invasiveness and
angiogenesis in pancreatic cancer. Int J Cancer. 124:853–861. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Grzesiak JJ, Smith KC, Burton DW, Deftos
LJ and Bouvet M: GSK3 and PKB/Akt are associated with
integrin-mediated regulation of PTHrP, IL-6 and IL-8 expression in
FG pancreatic cancer cells. Int J Cancer. 114:522–530. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang L, Tang C, Cao H, Li K, Pang X, Zhong
L, Dang W, Tang H, Huang Y, Wei L, et al: Activation of IL-8 via
PI3K/Akt-dependent pathway is involved in leptin-mediated
epithelial-mesenchymal transition in human breast cancer cells.
Cancer Biol Ther. 16:1220–1230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tsoumas D, Nikou S, Giannopoulou E,
Champeris Tsaniras S, Sirinian C, Maroulis I, Taraviras S, Zolota
V, Kalofonos HP and Bravou V: ILK Expression in colorectal cancer
is associated with EMT, Cancer stem cell markers and
chemoresistance. Cancer Genomics Proteomics. 15:127–141.
2018.PubMed/NCBI
|
|
40
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
